Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants. by Catherine Riou, Jinal N Bhiman, Yashica Ganga, Shobna Sawry, Frances Ayres, Richard Baguma, Sashkia R Balla, Ntombi Benede, Mallory Bernstein, Asiphe S Besethi, Sandile Cele, Carol Crowther, Mrinmayee Dhar, Sohair Geyer, Katherine Gill, Alba Grifoni, Tandile Hermanus, Haajira Kaldine, Roanne S Keeton, Prudence Kgagudi, Khadija Khan, Erica Lazarus, Jean Le Roux, Gila Lustig, Mashudu Madzivhandila, Siyabulela F J Magugu, Zanele Makhado, Nelia P Manamela, Qiniso Mkhize, Paballo Mosala, Thopisang P Motlou, Hygon Mutavhatsindi, Nonkululeko B Mzindle, Anusha Nana, Rofhiwa Nesamari, Amkele Ngomti, Anathi A Nkayi, Thandeka P Nkosi, Millicent A Omondi, Ravindre Panchia, Faeezah Patel, Alessandro Sette, Upasna Singh, Strauss van Graan, Elizabeth M Venter, Avril Walters, Thandeka Moyo-Gwete, Simone I Richardson, Nigel Garrett, Helen Rees, Linda-Gail Bekker, Glenda Gray, Wendy A Burgers, Alex Sigal, Penny L Moore, Lee Fairlie

Get full text